Background and Aims
The features of non-viral, nonalcohol hepatocellular carcinoma (NBNC-HCC) remain elusive. The aim of this study was to investigate this clinical characteristics and overall survival of NBNC-HCC compared to hepatitis B- (HBV-HCC) and hepatitis C-related (HCV-HCC) HCC.
We analyzed the etiologies, fibrosis stages, clinical data, and outcomes of newly diagnosed patients with HCC.
A total of 1777 HCC patients were recruited, including 332 patients with NBNC-HCC, 682 patients with HBV-HCC, 680 patients with HCV-HCC, and 83 patients with HBV/HCV HCC. Patients with NBNC-HCC were older (69.9 ± 11.9 years). Patients with NBNC-HCC exhibited a higher prevalence of diabetes (43.9%) compared to the HBV-HCC (27.1%, p < 0.05) and HCV-HCC (30.2%, p < 0.05) groups. Compared to patients from the viral-related HCC groups, patients with NBNC-HCC exhibited a significantly lower fibrosis stage. NBNC-HCC patients exhibited a higher proportion of Barcelona Clinic Liver Cancer (BCLC) classification stage C and stage D compared to patients from the HBV-HCC and HCV-HCC groups. With a mean of 2.33 ± 2.31 years of follow-up, the median survival of patients with NBNC-HCC was 1.75 (95% CI 1.33–2.17) years, which was significantly lower than that of patients with HBV-HCC (p = 0.041) and HCV-HCC (p < 0.001).
Patients with NBNC-HCC have a higher risk of diabetes than patients with HCC of viral etiologies. Although patients with NBNC-HCC exhibited a milder fibrosis stage, their more advanced HCC stages and worse overall survival should be taken into consideration in clinical care.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Nishikawa H, Osaki Y. Non-B, non-C hepatocellular carcinoma (Review). Intern J Oncol. 2013;43:1333–1342.
Cho EJ, Kwack MS, Jang ES, et al. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion. 2011;84:17–22.
Utsunomiya T, Shimada M. Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res. 2011;41:711–721.
Lu SN, Su WW, Yang SS, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Intern J Cancer. 2006;119:1946–1952.
Kimura T, Kobayashi A, Tanaka N, et al. Clinicopathological characteristics of non-B non-C hepatocellular carcinoma without past hepatitis B virus infection. Hepatol Res. 2017;47:405–418.
Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350–360.
Suzuki Y, Ohtake T, Nishiguchi S, et al. Survey of non-B, non-C liver cirrhosis in Japan. Hepatol Res. 2013;43:1020–1031.
Kim SK, Marusawa H, Eso Y, et al. Clinical characteristics of non-B non-C hepatocellular carcinoma: a single-center retrospective study. Digestion. 2011;84:43–49.
Nakagawa S, Wei L, Song WM, et al. Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition. Cancer Cell. 2016;30:879–890.
Wakiyama S, Matsumoto M, Haruki K, et al. Clinical features and outcome of surgical patients with non-B non-C hepatocellular carcinoma. Anticancer Res. 2017;37:3207–3213.
Nishio T, Hatano E, Sakurai T, et al. Impact of hepatic steatosis on disease-free survival in patients with non-B non-C hepatocellular carcinoma undergoing hepatic resection. Ann Surg Oncol. 2015;22:2226–2234.
Imura S, Shimada M, Utsunomiya T, et al. Clinicopathological characteristics of patients with non-B non-C hepatocellular carcinoma: a special reference to metabolic syndrome. Hepato-gastroenterology. 2014;61:129–135.
Okuda Y, Mizuno S, Shiraishi T, et al. Clinicopathological factors affecting survival and recurrence after initial hepatectomy in non-B non-C hepatocellular carcinoma patients with comparison to hepatitis B or C virus. BioMed Res Intern. 2014;2014:975380.
Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. Comparison of clinical characteristics and survival after surgery in patients with non-B and non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma. J Cancer. 2013;4:502–513.
Kaneda K, Kubo S, Tanaka H, et al. Features and outcome after liver resection for non-B non-C hepatocellular carcinoma. Hepato-gastroenterology. 2012;59:1889–1892.
Chang IC, Huang SF, Chen PJ, et al. The hepatitis viral status in patients with hepatocellular carcinoma: a study of 3843 patients from Taiwan liver cancer network. Medicine. 2016;95:e3284.
Yeh ML, Huang CI, Huang CF, et al. The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. PLoS ONE. 2017;12:e0184878.
Kuo YH, Kee KM, Wang JH, et al. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. Aliment Pharmacol Ther. 2018;48:993–1002.
Kwak HW, Park JW, Koh YH, Lee JH, Yu A, Nam BH. Clinical characteristics of patients with cryptogenic hepatocellular carcinoma in a hepatitis B virus-endemic area. Liver Cancer. 2016;5:21–36.
Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011;46:1230–1237.
Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012;42:368–375.
Chen CH, Huang GT, Yang PM, et al. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Euro J Cancer. 2006;42:2524–2529.
Oh KC, Park SH, Park JC, et al. Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea? Korean J Gastroenterol. 2005;45:45–51.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
Ma WL, Lai HC, Yeh S, Cai X, Chang C. Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. Endocr Relat Cancer. 2014;21:R165–R182.
Jun TW, Yeh ML, Yang JD, et al. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Intern. 2018;38:895–902.
Karagozian R, Derdak Z, Baffy G. Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63:607–617.
Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594-601.e1.
Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–838.
Ohkura Y, Sasaki K, Matsuda M, Hashimoto M, Watanabe G. Long-term prognosis after resection of cryptogenic hepatocellular carcinoma. BMC Surg. 2015;15:115.
Takeishi K, Maeda T, Shirabe K, et al. Clinicopathologic features and outcomes of non-B, non-C hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2015;22:S1116–S1124.
This study was supported partly by grants from The Ministry of Science and Technology, Taiwan (MOST104-2314-B-037-078-MY3, 107-2314-B-037-082-MY3), and Kaohsiung Medical University Hospital (S10606, S10709, KMUH106-6R07). The authors thank secretary help from Taiwan Liver Research Foundation (TLRF). The foundation did not influence how the study was conducted or the approval of the manuscript. The authors also thank Dr. Tyng-Yuan Jang and Dr. Ta-Ya Lin for their active contribution in revising the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of Institutional Review Board of Kaohsiung Medical University Chung-Ho Memorial Hospital (IRB Number: KMUHIRB-E(II)-20180281) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hsu, PY., Hsu, CT., Yeh, ML. et al. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. Dig Dis Sci 65, 2120–2129 (2020). https://doi.org/10.1007/s10620-019-05938-3
- Hepatocellular carcinoma
- Liver fibrosis
- Cancer staging
- Nonalcoholic fatty liver disease